Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results

Background Blockade of the lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1) is a potentially attractive mechanism for lowering inflammatory and lipid risk in patients with atherosclerosis. This study aims to assess the safety, tolerability, and target engagement of MEDI6570, a high‐af...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Andrea L. Vavere, Marvin Sinsakul, Emily L. Ongstad, Ye Yang, Vijayalakshmi Varma, Christopher Jones, Joanne Goodman, Vincent F. S. Dubois, Angelica L. Quartino, Sotirios K. Karathanasis, Liron Abuhatzira, Anna Collén, Charalambos Antoniades, Michael J. Koren, Ruchi Gupta, Richard T. George
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2023-02-01
Serier:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Fag:	atherosclerosis cardiovascular disease coronary CTA diabetes LOX‐1
Online adgang:	https://www.ahajournals.org/doi/10.1161/JAHA.122.027540
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!